Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $270,391 | 23 | 62.3% |
| Consulting Fee | $150,592 | 26 | 34.7% |
| Travel and Lodging | $10,352 | 14 | 2.4% |
| Food and Beverage | $1,150 | 22 | 0.3% |
| Honoraria | $1,000 | 1 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $475.00 | 2 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| United Therapeutics Corporation | $395,820 | 42 | $0 (2024) |
| Abbott Laboratories | $20,099 | 21 | $0 (2021) |
| Medtronic Vascular, Inc. | $11,366 | 20 | $0 (2017) |
| AI Therapeutics, Inc. | $5,000 | 1 | $0 (2022) |
| W. L. Gore & Associates, Inc. | $1,000 | 1 | $0 (2019) |
| Gilead Sciences Inc | $475.00 | 2 | $0 (2017) |
| Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,625 | 1 | United Therapeutics Corporation ($6,625) |
| 2023 | $3,075 | 2 | United Therapeutics Corporation ($2,875) |
| 2022 | $24,408 | 3 | United Therapeutics Corporation ($19,408) |
| 2021 | $32,865 | 3 | United Therapeutics Corporation ($26,115) |
| 2020 | $35,649 | 5 | United Therapeutics Corporation ($31,399) |
| 2019 | $59,104 | 17 | United Therapeutics Corporation ($54,135) |
| 2018 | $143,381 | 23 | United Therapeutics Corporation ($138,913) |
| 2017 | $128,853 | 34 | United Therapeutics Corporation ($116,350) |
All Payment Transactions
88 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/28/2024 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $6,625.00 | Research |
| 10/25/2023 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Cardio-pulmonary | ||||||
| 02/22/2023 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $2,875.00 | Research |
| 09/28/2022 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $6,500.00 | Research |
| 04/13/2022 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $12,908.33 | Research |
| 01/24/2022 | AI Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 11/11/2021 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| Category: Heart Failure | ||||||
| 10/27/2021 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $18,641.67 | Research |
| 03/10/2021 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $7,473.33 | Research |
| 10/14/2020 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $12,041.67 | Research |
| 07/08/2020 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $8,583.33 | Research |
| 06/25/2020 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $4,250.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 03/25/2020 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $10,750.00 | Research |
| 02/11/2020 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: PAH | ||||||
| 12/11/2019 | United Therapeutics Corporation | REMODULIN (Drug) | — | Cash or cash equivalent | $12,891.67 | Research |
| Category: PAH | ||||||
| 09/19/2019 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $661.50 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 09/19/2019 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $661.50 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 09/19/2019 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $441.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 09/19/2019 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $441.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 09/19/2019 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $441.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 09/19/2019 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $441.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 09/19/2019 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $441.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 09/19/2019 | Abbott Laboratories | CardioMEMS HF System (Device) | Consulting Fee | Cash or cash equivalent | $441.00 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 08/28/2019 | United Therapeutics Corporation | ORENITRAM (Drug) | — | Cash or cash equivalent | $10,375.00 | Research |
| Study: UNSPECIFIED RESEARCH PROJECTS • Category: PAH | ||||||
| 07/01/2019 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| Category: Devices | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Unspecified Research Projects | United Therapeutics Corporation | $135,101 | 10 |
| UNSPECIFIED RESEARCH PROJECTS | United Therapeutics Corporation | $23,125 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 16 | 20 | $4,920 | $1,154 |
| 2021 | 1 | 19 | 37 | $9,102 | $2,399 |
| 2020 | 1 | 19 | 29 | $7,134 | $1,441 |
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 16 | 20 | $4,920 | $1,154 | 23.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 19 | 37 | $9,102 | $2,399 | 26.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 19 | 29 | $7,134 | $1,441 | 20.2% |
About Dr. Robert Bourge, MD
Dr. Robert Bourge, MD is a Cardiovascular Disease healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598712424.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Bourge, MD has received a total of $433,960 in payments from pharmaceutical and medical device companies, with $6,625 received in 2024. These payments were reported across 88 transactions from 7 companies. The most common payment nature is "" ($270,391).
As a Medicare-enrolled provider, Bourge has provided services to 54 Medicare beneficiaries, totaling 86 services with total Medicare billing of $4,994. Data is available for 3 years (2020–2022), covering 3 distinct procedure/service records.
Practice Information
- Specialty Cardiovascular Disease
- Location Birmingham, AL
- Active Since 05/27/2006
- Last Updated 06/29/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1598712424
Products in Payments
- REMODULIN (Drug) $173,722
- CardioMEMS HF System (Device) $16,513
- ORENITRAM (Drug) $10,375
- NONE (Drug) $8,879
- Mitra Clip system (Device) $3,586
- Product in Development (Device) $1,000
- Adempas (Drug) $200.00
- Letairis (Drug) $200.00
- TYVASO (Drug) $144.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Birmingham
Dr. Anil Rajendra, M.d, M.D
Cardiovascular Disease — Payments: $457,890
Vikram Arora, Md, MD
Cardiovascular Disease — Payments: $299,075
Dr. William Maddox, M.d, M.D
Cardiovascular Disease — Payments: $172,753
Dr. Gustavo Morales, Md, MD
Cardiovascular Disease — Payments: $124,880
Thomas Cawthon, M.d, M.D
Cardiovascular Disease — Payments: $105,922
Vera Bittner
Cardiovascular Disease — Payments: $105,808